OCX-063 is under clinical development by OccuRx and currently in Phase I for Diabetic Retinopathy. According to GlobalData, Phase I drugs for Diabetic Retinopathy have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OCX-063’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OCX-063 overview
OCX-063 is under development for the treatment of diabetic retinopathy, chronic kidney disease and focal segmental glomerulosclerosis (FSGS). It is administered through oral route and formulated in the form of capsule. It was under development for diabetic nephropathy, non-proliferative diabetic retinopathy, proliferative vitreoretinopathy, wet (neovascular / exudative) macular degeneration
OccuRx overview
OccuRx (OccuRx Pty) is a biopharmaceutical company that focuses on the development of innovative therapeutic strategies. The company is headquartered in Melbourne, Victoria, Australia.
For a complete picture of OCX-063’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
